Originally published 2021-11-27.
In late November 2021 the European Union signalled that it would support a narrowly targeted waiver of COVID-19 vaccine patents at the World Trade Organization. The idea was simple: a developing country that wanted a local company to make vaccines could authorise it quickly, without first winning the patent holder's consent and without fear of being sued. It was a notable softening for Brussels, which had spent more than a year opposing a broad suspension of intellectual property rules. WTO members did eventually agree such a measure, on 17 June 2022, but in a form far narrower than its original backers had wanted.
This page explains what the EU said at the time, why the patent question became so heated during the pandemic, what the WTO finally decided and why many health campaigners still felt let down.
What the EU offered in November 2021
Euronews reported on 26 November 2021, citing sources involved in the talks, that a deal on a targeted waiver could come within days. Negotiators were meeting at WTO headquarters in Geneva, where the rules on patents and trade are set by consensus among more than 160 members.
The EU's message was that it wanted something workable rather than symbolic. Its stated aim was a waiver focused tightly on boosting vaccine production, so that any country deciding it needed to license a manufacturer, including for export, could do so rapidly and effectively. According to the same report, the EU was open to a form of compulsory licensing with conditions, such as production at cost rather than for profit.
At the same time the bloc held on to its core argument. In the words of its position, without intellectual property protection "we wouldn't have a vaccine". In other words, Brussels was willing to make it easier to override patents in an emergency, but it did not accept that patents themselves were the main obstacle.
Why vaccine patents became a global fight
The debate began in October 2020, when India and South Africa asked the WTO to suspend parts of the Agreement on Trade-Related Aspects of Intellectual Property Rights, known as TRIPS, for the duration of the pandemic. Their proposal covered not only patents but also trade secrets, copyright and industrial designs, and it applied to vaccines, treatments and tests.
More than 100 developing countries backed the idea. Rich countries with large pharmaceutical industries, including members of the G7, resisted it. In May 2021 the United States under President Joe Biden surprised many by saying it would support a waiver for vaccines, which put the EU, the United Kingdom and Switzerland under pressure to move.
The emotional backdrop was the stark gap in vaccine access. While wealthy nations were rolling out booster doses in late 2021, many low-income countries had vaccinated only a small fraction of their populations. For campaigners, letting more factories produce vaccines was a matter of fairness and of ending the pandemic sooner, since unvaccinated populations give the virus more room to spread and mutate.
The case against a broad waiver
Drug companies and several governments argued that patents were not what was holding back supply. Modern vaccines, especially mRNA products, depend on scarce raw materials, specialised equipment, trained staff and know-how that a patent document does not transfer. In their view, removing patent protection would do little in the short term, could damage the partnerships that had produced vaccines in record time, and might discourage investment before the next pandemic. Some industry voices also worried that a waiver would benefit large manufacturing economies such as China rather than the poorest countries.
Compulsory licensing: what already existed
To understand why the EU talked about a "targeted" waiver, it helps to know that TRIPS already contained an emergency exit. Under Article 31, a government can issue a compulsory licence that lets a company use a patented invention without the owner's permission, usually in return for fair payment. The 2001 Doha Declaration on TRIPS and Public Health reaffirmed that countries have the right to do this to protect public health.
In practice, the tool is clumsy. Licences are generally granted country by country and product by product, and the rules originally limited exports, which is a problem for small countries without their own factories. A later amendment, Article 31bis, which entered into force in 2017, created a route for exporting medicines to countries that cannot make them, but it is slow and has rarely been used. Oxfam's Max Lawson told Euronews that the existing process could take months. The EU's November 2021 offer was essentially about streamlining this machinery rather than tearing it up.
What the WTO finally agreed in June 2022
The deal predicted for "next week" did not arrive that quickly. The WTO's 12th Ministerial Conference, scheduled for late 2021, was postponed when the Omicron variant emerged, and the decision was finally adopted in Geneva on 17 June 2022. Its main points were:
- Vaccines only. It covers patents needed to produce COVID-19 vaccines. Trade secrets, copyright and industrial designs, all part of the original proposal, were left out.
- Developing countries. Eligible members are developing countries, which declare their own status. Countries with existing vaccine capacity were encouraged to opt out, and language supported by the United States effectively kept China from using it.
- Faster authorisation. An eligible country can authorise production through any legal instrument, such as an emergency decree, even if it has no compulsory licensing law in place.
- Exports allowed. Any share of the output can be exported to other eligible members, with steps to prevent re-export to richer markets.
- Five years. The decision runs for five years, with the possibility of extension.
Members also promised to decide within six months whether to extend the same rules to COVID-19 tests and treatments. That deadline passed without agreement, and the extension was never adopted.
Did the waiver make a difference?
By the time the decision was signed, the vaccine supply picture had changed. Global production had expanded enormously and the COVAX facility was struggling more with delivery, storage and demand than with a lack of doses. Supporters of the patent system argued that this showed the waiver was a solution to a problem that had already passed.
Campaigners saw it differently. Amnesty International, Médecins Sans Frontières and many public health lawyers called the result a diplomatic compromise that added little to the flexibilities countries already had, and criticised the exclusion of tests and treatments. For them, the lesson was that the rules should be ready before the next pandemic, not negotiated for nearly two years while it is under way.
What the episode does show is how the politics moved. A proposal that rich countries flatly rejected in 2020 became, through US support and then EU engagement in late 2021, an agreed WTO decision. It was narrower than many hoped, but it established that the trading system will bend, at least a little, in a global health emergency.
Key points at a glance
- In November 2021 the EU said it was ready to back a targeted waiver to let developing countries license vaccine production quickly.
- The EU still insisted that patents were essential to vaccine development.
- India and South Africa had first proposed a much broader waiver in October 2020.
- The WTO adopted a vaccines-only decision on 17 June 2022, valid for five years.
- Talks on extending it to tests and treatments did not produce agreement.
Sources: Euronews (Shona Murray), 26 November 2021: EU to support targeted patent waiver on Covid vaccines, say sources; Fasken, June 2022: Limited TRIPS waiver for COVID-19 vaccines; OBWB: WTO reaches agreement on temporary TRIPS waiver regarding COVID-19 vaccines; Wikipedia: TRIPS Agreement.

COMMENTS